NovoCure Limited
NVCR
$11.19
-$0.49-4.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 642.27M | 630.16M | 621.71M | 605.22M | 577.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 642.27M | 630.16M | 621.71M | 605.22M | 577.74M |
| Cost of Revenue | 157.23M | 147.88M | 141.06M | 136.23M | 135.53M |
| Gross Profit | 485.04M | 482.28M | 480.65M | 468.99M | 442.21M |
| SG&A Expenses | 445.94M | 441.41M | 434.72M | 428.89M | 383.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 818.03M | 801.99M | 787.60M | 774.76M | 729.93M |
| Operating Income | -175.76M | -171.83M | -165.89M | -169.54M | -152.19M |
| Income Before Tax | -150.50M | -142.07M | -129.82M | -131.16M | -114.49M |
| Income Tax Expenses | 27.15M | 28.89M | 34.37M | 37.47M | 35.29M |
| Earnings from Continuing Operations | -177.65 | -170.95 | -164.19 | -168.63 | -149.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -177.65M | -170.95M | -164.19M | -168.63M | -149.78M |
| EBIT | -175.76M | -171.83M | -165.89M | -169.54M | -152.19M |
| EBITDA | -163.59M | -160.87M | -155.51M | -159.68M | -142.61M |
| EPS Basic | -1.61 | -1.56 | -1.51 | -1.56 | -1.39 |
| Normalized Basic EPS | -1.00 | -0.96 | -0.90 | -0.92 | -0.79 |
| EPS Diluted | -1.61 | -1.56 | -1.51 | -1.56 | -1.39 |
| Normalized Diluted EPS | -1.00 | -0.96 | -0.90 | -0.92 | -0.79 |
| Average Basic Shares Outstanding | 442.24M | 438.58M | 434.70M | 431.69M | 430.20M |
| Average Diluted Shares Outstanding | 442.24M | 438.58M | 434.70M | 431.69M | 430.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |